VahatiCor Inc

This Thanksgiving, we're grateful for the opportunity to champion the voices of those living with coronary microvascular dysfunction (CMD), a condition often overlooked yet life-altering for millions. We're inspired by the physicians, patients, researchers, and advocates who share our mission to make CMD a recognized problem. Your commitment inspires us to push for awareness, innovation, and improved solutions. As we reflect on this season of gratitude, we extend our heartfelt thanks to everyone who has joined us in shining a light on microvascular disease. Together, we're making an impact, one step at a time. Wishing you and your loved ones a warm, meaningful Thanksgiving! #happythanksgiving #thanksgiving2024 #AFluxReducer #CMD #CoronaryMicrovascularDysfunction #interventionalcardiology

We're excited to welcome Angela Mallery, Ed.D., as VahatiCor's new Vice President of Regulatory and Quality Affairs. Angela has a knack for turning red tape into a clear path forward. She's spent her career navigating the regulatory maze and advancing medical innovations with ease, precision, and integrity. Her expertise will be pivotal as we guide the A-FLUX Reducer toward its next phase of studies, ensuring we meet the highest quality and compliance standards. Welcome to the team, Angela—we're thrilled to have you with us! ? #Leadership #TeamAnnouncement #RegulatoryAffairs #QualityAssurance #MedicalDevices #HealthcareInnovation #MedTech #WelcomeToTheTeam

Take a listen to Dr. Jean-Michel Paradis, an interventional cardiologist at the Quebec Heart and Lung Institute, Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval in Canada. Dr. Paradis and his team performed the first-in-human cases of the A-FLUX Coronary Sinus Reducer. ?? “So far, I’ve treated three patients with the A-FLUX device—two with severe obstructive coronary disease and one with microvascular dysfunction. All three procedures were successful, and the patients are doing very well.” Learn about his journey treating patients with severe obstructive coronary disease and microvascular dysfunction and why CMD is a hot topic in interventional cardiology. VahatiCor is committed to building the clinical evidence for this novel therapy and addressing the unmet needs of patients with coronary microvascular dysfunction. Watch the full interview below. #TCT2024 #InterventionalCardiology #MicrovascularDysfunction #AFLUX #Coronarysinusreducer #reducertherapy #CMD #Innovation #PatientCare #AFLUXReducer Disclaimer: VahatiCor’s A-Flux Reducer System? is not FDA-approved for commercial use.

Thank you, Cardiac Interventions Today, for shining a light on the A-FLUX Reducer System from VahatiCor and the unmet needs of patients with Coronary Microvascular Dysfunction (CMD). CMD, more prevalent in women, causes significant symptoms both at rest and during exertion. They have a real need for an effective treatment. We are committed to building the clinical evidence for this novel therapy. #VahatiCor #AFLUXReducer #Cardiology #CMD #microvascular #coronary #CoronaryMicrovascularDysfunction #MedicalInnovation #PatientCare #interventionalcardiology

In our recent conversation at TCT, Dr. Francesco Giannini shared key insights on his work with coronary sinus reducer therapy. With over a decade of experience in the field, Dr. Giannini discussed promising results from the compassionate use of the A-FLUX system. He noted that, "At one month, most patients showed significant angina relief, with these improvements in quality of life sustained at six months." Catch the full interview for more on Dr. Francesco Giannini's perspective on CMD treatment advancements and what’s next for patient care. #TCT2024 #Cardiology #CMD #AFLUX #VahatiCor #microvascular #CoronaryMicrovascularDysfunction #HealthcareInnovation #interventionalcardiology

Coronary microvascular dysfunction is a significant unmet need impacting the quality of life of many patients. Listen to Dr. Samit Shah MD, PhD discuss patient symptoms and the importance of gathering clinical evidence supporting coronary sinus reducer therapy. #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology

This morning, Dr. Francesco Giannini delivered a powerful presentation on the first-in-man experience of the A-FLUX coronary sinus reducer. He shared the positive results from the compassionate use study, showing us how this therapy addresses one of the unmet needs in cardiology today: coronary microvascular dysfunction. A huge thank you to Dr. Francesco Giannini and the team behind the data. #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer

A new therapy on the horizon for microvascular patients? Join Dr. Francesco Giannini tomorrow morning as he presents the first-in-man experience of the A-FLUX Coronary Sinus Reducer. This session will review how the first patients, including coronary microvascular patients, were treated with A-FLUX therapy and how it impacted their symptoms. Come and see! ???October 30, 2024, 9:24 AM – 9:29 AM ?? Walter E. Washington Convention Center | Moderated Abstracts Station 6 #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology

We’re thrilled to share positive results from our compassionate use study of the A-FLUX Reducer System?, which showed significant symptom relief for patients with coronary microvascular dysfunction (CMD) and persistent obstructive coronary artery disease. Link to the press release here: https://lnkd.in/dScnATSz Thank you, Dr. Samit Shah and Dr. Tim Van de Hoef, for leading the SERRA I study with the A-FLUX Coronary Sinus Reducer. It is an important first step in our journey to help patients suffering from coronary microvascular dysfunction. #VahatiCor #AFLUXReducer #Cardiology #CMD #HeartHealth #MedicalInnovation #ClinicalResearch

Dr. Manel Sabate presented today the excellent results of the first patient with coronary microvascular dysfunction treated with VahatiCor’s A-FLUX Coronary Sinus Reducer. A heartfelt thank you to Dr. Sabate and to the whole team at the Hospital Clínic de Barcelona for this important step in addressing this underdiagnosed and undertreated patient group. #TCT2024 #Cardiology #CoronaryMicrovascularDysfunction #CMD #AFLUXReducer #VahatiCor #HeartHealth #InterventionalCardiology #PatientCare #HealthcareAdvancement